Imatinib Accord 100 & 400 100 mg/400 mg FC tablets.
PDF Leaflet Revision Date: 26 August 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of various cancers including CML and GIST.
Dosage (summary)
400 mg daily for chronic phase CML; 600 mg for accelerated phase; 800 mg for DFSP.
Special Populations
- Children
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding; use effective contraception.
Key Drug Interactions
- CYP3A4 inhibitors
- CYP3A4 inducers
- Warfarin
Contraindications
- Hypersensitivity to imatinib
- Pregnancy
- Lactation
Common side effects
- Nausea
- Diarrhea
- Fatigue
- Fluid retention
- Neutropenia
Counselling Points
- Take with food and water
- Monitor for signs of bleeding
- Regular blood tests required
Serious warnings
- Hepatotoxicity
- Cardiac issues
- Tumor lysis syndrome
- Hypothyroidism
Important Disclaimer
The Imatinib Accord 100 & 400 100 mg/400 mg FC tablets. professional information leaflet below is the property of Accord Healthcare and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
